Fucoidan Imaging Agents for Selectin Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging agents for selectins, such as anti-selectin antibodies and sialyl Lewis X analogs, are complex and costly to produce, limiting their industrial development and commercialization for non-invasive diagnosis of cardio/neurovascular pathologies and cancer metastasis.
Innovation Solution
Development of a selectin-targeted imaging agent comprising low molecular weight fucoidan associated with a detectable moiety, specifically ultrasmall superparamagnetic iron oxide particles (USPIO) for MRI, which binds to P-selectin with high affinity and specificity, allowing for in vivo detection of conditions like thrombosis and cancer metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If anti-selectin antibodies or sialyl Lewis X analogs are used as imaging agents, then selectin detection specificity is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent employs fucoidan, a naturally occurring polysaccharide from brown seaweed, as a selective ligand for P-selectin. Fucoidan is significantly easier and cheaper to produce compared to synthetic sialyl Lewis X analogs or purified anti-selectin antibodies, while maintaining high binding affinity (Kd ~1-10 nM) and specificity for P-selectin, thus resolving the contradiction between detection precision and manufacturing complexity
Solution Approach 2:
The patent utilizes the calcium-dependent binding property of fucoidan to P-selectin, leveraging the physiological calcium concentration in blood to achieve specific binding. This natural biochemical parameter (calcium dependence) enables selective detection without requiring complex synthetic structures, simplifying the imaging agent while maintaining precision
2Measurement precision
If anti-selectin antibodies or sialyl Lewis X analogs are used as imaging agents, then selectin detection accuracy is improved, but production cost increases
Solution Approach 1:
Fucoidan is extracted from abundant natural sources (brown seaweed) using simple enzymatic or chemical methods, eliminating the need for expensive cell culture, antibody purification, or complex synthetic chemistry required for anti-selectin antibodies or sialyl Lewis X analogs, thus dramatically reducing production cost while maintaining detection accuracy
Solution Approach 2:
Instead of using complex synthetic copies of sialyl Lewis X or purified antibodies, the patent uses fucoidan which naturally presents carbohydrate structures that mimic the binding interface. This natural copy approach simplifies production while maintaining the essential binding function for accurate selectin detection
3Reliability
If conventional imaging agents are used, then selectin visualization capability is improved, but industrial development and commercialization are hindered
Solution Approach 1:
The patent creates a complete imaging system based on fucoidan that can be manufactured at industrial scale using straightforward extraction and conjugation protocols. The system includes fucoidan preparation, radiolabeling or fluorescent conjugation, and administration protocols, all of which are significantly simpler than existing approaches, thereby enabling commercialization while maintaining reliable selectin visualization
Solution Approach 2:
The patent divides the imaging agent into modular components: fucoidan (from seaweed), carrier molecule (for administration and stability), and detectable moiety (radiolabel or fluorophore). This segmentation allows independent optimization and scaling of each component, facilitating industrial development while preserving the core function of selectin targeting and visualization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fucoidan-based imaging agent enables efficient and cost-effective non-invasive detection of selectins in vivo, effectively visualizing conditions like thrombosis, myocardial ischemia, and cancer metastasis, with a dissociation constant suitable for clinical application.
Implementation Method 1
At their extracellular amino termini, they have a single calcium-dependent (or C-type) lectin domain (L)... Selectin-mediated cell adhesion results from calcium-dependent interactions of the amino-terminal lectin domain with a large variety of carbohydrate-presenting molecules
Implementation Method 2
the at least one detectable moiety is detectable by Magnetic Resonance Imaging (MRI) and comprises an ultrasmall superparamagnetic iron oxide particle (USPIO)
Data Source
Figure 1
Figure 2A~2D
Figure 3
AI summary
The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.